Medium-term performance targets for net sales and operating profit
First written in FY2017. 8 of 21 entries say "Raised", first in FY2021-Q2. Latest entry: FY2026.
The whole theme swung hardest in 2021: 17 of 77 companies on the "Worse" side.
8 other companies' latest entry also says "Raised".
- FY2026RaisedAnnual report
「For the fiscal year ending March 2027, consolidated net sales are forecast at ¥14,000 million and operating income at ¥260 million.」
The targets were updated from the previous fiscal year's figures for the fiscal year ending March 2026 of net sales of ¥13,500 million and operating income of ¥150 million to net sales of ¥14,000 million and operating income of ¥260 million for the fiscal year ending March 2027. - FY2025SoftenedAnnual report
「For the fiscal year ending March 2026, consolidated net sales are forecast at ¥13,500 million and operating income at ¥150 million.」
The forecast for net sales for the fiscal year ending March 2026 was maintained at ¥13,500 million, while the forecast for operating income fell to ¥150 million from ¥350 million for the fiscal year ending March 2025 stated in the previous fiscal year. - FY2025-H1RestatedAnnual report
「There were no material changes during the interim consolidated accounting period under review to the objective indicators and other measures used to assess progress toward management targets.」
The company has reaffirmed that there were no material changes to the objective indicators and other measures used to assess progress toward management targets. - FY2024RaisedAnnual report
「For the fiscal year ending March 2025, consolidated net sales are forecast at ¥13,500 million and operating income at ¥350 million.」
For the fiscal year ending March 2025, the company set targets of net sales of ¥13,500 million and operating income of ¥350 million, compared with the revised forecast for the fiscal year ending March 2024 of net sales of ¥13,000 million and an operating loss of ¥50 million, substantially raising the profit target. - FY2024-Q3SoftenedAnnual report
「Forecast for the fiscal year ending March 2024 Initial estimate (A) Forecast for the fiscal year ending March 2024 Revised estimate (B) Change (B) − (A) Change (%) (B) / (A) Net sales ¥12,500 million ¥13,000 million ¥500 million Up 4.0% Operating income ¥300 million △¥50 million △¥350 million —」
The net sales forecast for the fiscal year ending March 2024 was raised from ¥12,500 million to ¥13,000 million, while the operating income forecast was substantially lowered from ¥300 million to a loss of ¥50 million. - FY2024-Q2RestatedAnnual report
「There were no material changes during the cumulative second quarter of the consolidated fiscal year under review to the objective indicators and other measures used to assess progress toward management targets.」
The company has reaffirmed that there were no material changes to the objective indicators and other measures used to assess progress toward management targets. - FY2024-Q1RestatedAnnual report
「There were no material changes during the cumulative consolidated period through the first quarter to the objective indicators and other measures used to assess progress toward the Company's management objectives.」
The company has reaffirmed that there were no material changes to the objective indicators and other measures used to assess progress toward management targets. - FY2023-Q3SoftenedAnnual report
「Forecast for the fiscal year ending March 2023 Initial estimate (A) Forecast for the fiscal year ending March 2023 Revised estimate (B) Change (B) − (A) Change (%) (B) / (A) Net sales ¥11,500 million ¥11,700 million ¥200 million Up 1.7% Operating income ¥550 million ¥210 million △¥340 million Down 61.8%」
The net sales forecast was raised from ¥11,500 million to ¥11,700 million, while the operating income forecast was substantially lowered from ¥550 million to ¥210 million. The profit target has weakened. - FY2023-Q2RestatedAnnual report
「There were no material changes during the cumulative second quarter of the consolidated fiscal year under review to the objective indicators and other measures used to assess progress toward management targets.」
The company states that there were no material changes to the objective indicators and other measures used to assess progress toward management targets. - FY2022-Q3SoftenedAnnual report
「Forecast for the fiscal year ending March 2022 Initial estimate (A) ¥12,000 million ¥1,200 million Forecast for the fiscal year ending March 2022 Revised estimate (B) ¥12,700 million ¥1,900 million Change ¥700 million ¥700 million Change (%) Up 5.8% Up 58.3%」
Compared with the initial forecast, net sales were raised to ¥12,700 million and operating income to ¥1,900 million, but both were lowered from the previous quarter's forecast of net sales of ¥13,400 million and operating income of ¥2,100 million. The revised estimates were ¥1,850 million for ordinary income and ¥2,100 million for net income attributable to owners of the parent. - FY2022-Q2RaisedAnnual report
「Forecast for the fiscal year ending March 2022 Initial estimate (A) ¥12,000 million ¥1,200 million Forecast for the fiscal year ending March 2022 Revised estimate (B) ¥13,400 million ¥2,100 million Change ¥1,400 million ¥900 million Change (%) Up 11.7% Up 75.0%」
The full-year forecast for the fiscal year ending March 2022 was raised from net sales of ¥12,000 million to ¥13,400 million and from operating income of ¥1,200 million to ¥2,100 million. The company cited PCR testing volumes exceeding expectations, as well as steady clinical trial orders and utilization rates. - FY2022-Q1RaisedAnnual report
「Forecast for the fiscal year ending March 2022 Initial estimate (A) ¥12,000 million ¥1,200 million Revised estimate (B) ¥13,000 million ¥1,700 million Change ¥1,000 million ¥500 million Change (%) Up 8.3% Up 41.7%」
The full-year forecast for the fiscal year ending March 2022 was raised from net sales of ¥12,000 million to ¥13,000 million and from operating income of ¥1,200 million to ¥1,700 million. The company cited PCR testing volumes substantially exceeding expectations and steady clinical trial orders. - FY2021RaisedAnnual report
「Actual results for the fiscal year ended March 2021 Net sales ¥11,046 million Operating income ¥893 million Forecast for the fiscal year ending March 2022 Net sales ¥12,000 million (up 8.6% year on year) Operating income ¥1,200 million (up 34.3% year on year)」
Following record-high profit in the fiscal year ended March 2021, targets for the fiscal year ending March 2022 were set at net sales of ¥12,000 million and operating income of ¥1,200 million. The operating income target was raised from the previous quarter's forecast of ¥700–¥900 million. - FY2021-Q3RaisedAnnual report
「Actual results for the fiscal year ended March 2020 ¥11,046 million ¥173 million Forecast for the fiscal year ending March 2021 Net sales ¥10,900 million–¥11,200 million (down 1.3%–up 1.4% year on year) Operating income ¥700 million–¥900 million (up 302.8%–up 417.9% year on year)」
The performance forecast was raised from the previous quarter's forecast for the fiscal year ending March 2021 of net sales of ¥10,500 million and operating income of ¥450 million to net sales of ¥10,900–¥11,200 million and operating income of ¥700–¥900 million. However, it is presented as a range in light of the impact of infectious diseases. - FY2021-Q2RaisedAnnual report
「Actual results for the fiscal year ended March 2020 Forecast for the fiscal year ending March 2021 Net sales ¥11,046 million ¥10,500 million (down 4.9% year on year) Operating income ¥173 million ¥450 million (up 159.0% year on year)」
The full-year forecast for the fiscal year ending March 2021, which had previously been left undecided, was reinstated at net sales of ¥10,500 million and operating income of ¥450 million. The operating income forecast is above the previous fiscal year's actual result of ¥173 million. - FY2020SoftenedAnnual report
「Actual results for the fiscal year ended March 2020 Forecast for the fiscal year ending March 2021 Net sales ¥11,046 million (up 27.3% year on year) Undecided Operating income ¥173 million (down 35.7% year on year) Undecided For the consolidated fiscal year under review, net sales increased 27.3% year on year, but operating income declined 35.7% year on year, and the target was not achieved.」
The policy of using growth in net sales and operating income as management indicators was maintained, but operating income declined in the fiscal year under review, and the forecast for the fiscal year ending March 2021 was left undecided. - FY2019Update to target figuresAnnual report
「Actual results for the fiscal year ended March 2019 Forecast for the fiscal year ending March 2020 Net sales ¥8,674 million (up 140.9% year on year) ¥9,850 million (up 13.6% year on year) Operating income ¥270 million (up 346.0% year on year) ¥350 million (up 29.6% year on year)」
The performance targets for the fiscal year ending March 2020 were updated to net sales of ¥9,850 million and operating income of ¥350 million. The update incorporates an expansion in sales scale, while the metric framework has changed from the previous medium-term targets. - FY2019-Q1RestatedAnnual report
「In its Medium-term Management Vision 2020, announced in May 2017, the Group set out plans to provide differentiated, high-value-added services centered on its core CRO business and to pursue an M&A strategy. To build a sustainable growth structure, it had been considering partnerships with companies possessing superior technologies that would complement the Company's business development.」
The company has reaffirmed the high-value-added strategy centered on CRO services and the M&A strategy under Medium-term Management Vision 2020 as the background to the acquisition of the 安評センター business. - FY2017First statedAnnual report
「(Medium-term performance targets) Actual results for the fiscal year ended March 2017 Forecast for the fiscal year ending March 2018 Target for the fiscal year ending March 2019 Target for the fiscal year ending March 2020 Net sales ¥2.30 billion ¥2.41 billion ¥2.70 billion ¥3.00 billion Operating income ¥150 million ¥200 million ¥310 million ¥450 million」
The company has for the first time explicitly stated medium-term performance targets of ¥3.00 billion in net sales and ¥450 million in operating income for the fiscal year ending March 2020.